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OBJECTIVES: In the LIFE study, losartan-based antihyperten-
sive therapy reduced the primary composite endpoint of cardio-
vascular death, myocardial infarction, or stroke by 13% (p =
0.02) and reduced the risk of stroke by 25% (p = 0.001), despite
comparable degree of blood pressure control in hypertensive
patients with left ventricular hypertension (LVH) over 5.5 years.
The objective of this study was to estimate LIFE target popula-
tion (55–80 years, Diastolic BP /Systolic BP: 95–115/ 160–200
mmHg, ECG-LVH without heart failure or angina pectoris) and
to project the reduction in stroke observed with losartan versus
atenolol-based therapy in the LIFE study in France. METHODS:
The population aged 55–80 was extracted from national statis-
tics. Prevalence of hypertension was estimated by extrapolating
the WHO MONICA data (Lille, Strasbourg, Toulouse) to this
segment of the population. The number of patients with con-
gestive heart failure and/or angina pectoris calculated from
Thales (computerized data base) was substracted. Prevalence of
LVH was based on the LIFE pilot study results. Number of
strokes averted was estimated by multiplying the number of
patients meeting LIFE inclusion criteria by the cumulative inci-
dence risk difference in stroke from LIFE at 5.5 years. RESULTS:
The French population aged 55–80 is comprised of 13 million
people. Half are hypertensive. We conservatively projected that
1.4 million individuals meet LIFE study criteria. Using losartan
based therapy in this target population, the projected cumulative
number of strokes over 5.5 years would be 67,957, compared to
90,147 with atenolol, a difference of stroke averted of 22,190.
CONCLUSIONS: The reduction with a losartan-based vs.
atenolol-based regimen should be viewed as representing an
incremental improvement relative to the beneﬁt of conventional
antihypertensives therapies, betablockers and diuretics. A popu-
lation wide prevention of using losartan in hypertensive patients
with LVH has the potential to have a major public health impact
by reducing stroke incidence in France.
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OBJECTIVES: Despite evidence-based guidelines the use of anti-
coagulation therapy in the prevention of strokes in patients with
nonvalvular atrial ﬁbrillation (AFib) is sub-optimal. The therapy
involves a trade-off between the potential beneﬁts of reducing
the risk of ischemic stroke versus the risk of haemorrhagic bleed-
ing. The aim of the study was to identify and describe physicians’
attitudes and beliefs in the assessment of risks connected with
anti-coagulation treatment. METHODS: A telephone interview
was conducted with a cross-section of GP’s, internists and car-
diologists randomly selected from a sub-set of 7,072 out of the
59,953 ofﬁce-based physicians of these specialities in Germany.
RESULTS: A total of 75 people completed the surveys (15.1%
of 498 eligible respondents). Only 25% of the physicians iden-
tiﬁed the right relative risk-reduction of anticoagulation (INR
2–3) while 52% of the physicians agreed strongly with the state-
ment that intracranial bleeding was more regrettable than
ischemic stroke. This was independent of former experiences
with bleeding complications. However, questioning physicians’
personal risk acceptance, most respondents would choose for
themselves a more effective therapy with higher risks (68%), like
anticoagulation therapy in case of AFib, accepting the risk of
bleeding (48%). Fear of bleeding complications was not inde-
pendent of questions of INR-control. Although 89.3% stressed
the high compliance which is needed for anticoagulation therapy,
only 13.4% of physicians disagreed strongly with the statement
that anticoagulation can be used without problems. CONCLU-
SIONS: Results show general acceptance of anticoagulation
treatment by German ofﬁce-based physicians. However, physi-
cians’ assessment of burden of therapy, like difﬁculty in INR-
control or need for patients’ compliance, leads to reservations
against anticoagulation. Also deﬁcits in knowledge of potential
beneﬁts of anticoagulation may contribute to sub-optimal usage
patterns.
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DECISION ANALYSIS AND COSTS OF LOW MOLECULAR
WEIGHT HEPARINS: A CASE STUDY IN FRANCE
Launois R, Gerlier L
REES France, Paris, France
OBJECTIVES: The aim of the study was to emphasize the neces-
sity of deﬁning the market when estimating the cost of two drugs.
One can appear cheaper than another when only a certain part
of the market is considered, and becoming the most expensive
after all societal costs have been taken into account. METHODS:
We focused on the sales of two widespread Low Molecular
Weight Heparins (LMWH) in France from an ambulatory point
of view. We then added the number of syringes distributed in
hospitals, and compared the new costs obtained. A decision tree
with market shares as probabilities made the calculation of
weighted mean costs particularly clear. RESULTS: When only
syringes sold by an ambulatory were considered, the daily cost
of enoxaparine preventive dosages was 31% more expensive
than that of tinzaparine (4.77€ vs. 3.63€). There was a 21% dif-
ference for curative dosages (13.18€ vs. 10.85€). When all the
sold syringes -hospital and open care- have been integrated in
the calculation of mean costs, the conclusion was completely
opposite: the daily cost for tinzaparine was 90% more expensive
than that of enoxaparine on preventive dosages (3.62€ vs.
1.91€). For curative dosages, tinzaparine daily cost reaches more
than twice the enoxaparine daily cost (10.09€ vs. 4.62€). Global
weighted daily costs of enoxaparine and tinzaparine regardless
of indication and market are respectively 2.18€ and 6.21€. CON-
CLUSIONS: The segmentation of the health care system and the
practice of different prices according to the type of markets
(ambulatory, hospital) prevent the public decision-makers to
have a clear view of the real cost of the drugs from a societal
viewpoint.
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OBJECTIVES: To assess the effects of increasing the statin
potency in the management of hypercholesterolemia in general
practice and cardiology outpatient settings in Germany.
METHODS: A total of 603 randomly drawn patients from 
62 selected general and cardiology practices in Germany. All
patients had established coronary heart disease, initiated on
lipid-lowering therapy (LLT) between July 1, 1998 and June 30,
1999, had at least one LDL-C measurement in the preceding year
and were treated for secondary prevention for at least two years
(or until the patient’s death) after LLT initiation. Out of 603
patients, 153 had a ﬁnal switch to a higher potency statin (either
the same statin or a different one) and are analyzed here.
RESULTS: The 153 patients had a mean baseline LDL-C 
of 170.8mg/dL, mean age of 63 years, mean baseline TC of
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263.8mg/dL, 42% were females and 31.3% were diagnosed with
diabetes mellitus. The mean pre-switch LDL-C was 143mg/dL,
mean post-switch LDL-C was 126.6mg/dL, mean percentage
reduction was 7.8%, and the mean time before the ﬁnal switch
was 143.6 days (median 80 days). In a paired comparison test,
the reduction in post-switch LDL-C was signiﬁcant at < 1%. In
a multivariate analysis, the time to switch to higher potency after
LDL-C measurement has no signiﬁcant effect on post-switch
LDL-C reduction. After switch 42 (27.45%) attained goal LDL-
C level. CONCLUSIONS: Switching to higher potency statins
reduces LDL-C levels by only an additional eight percent (8%)
resulting in majority (72.55%) of the patients in clinical practice
failing to attain recommended LDL-C goal even after up titra-
tion on statins.
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OBJECTIVES: Assess TC goal (<5mmol/L) attainment among
CHD/CHD equivalent patients and nonCHD patients with mul-
titple risk factors that were prescribed lipid-lowering drugs
(LLD). METHODS: Retrospective cohort study at 44 randomly
selected centres across Hungary (30 primary care and 14 outpa-
tient lipid centres). Physicians at selected centers consecutively
identiﬁed 10 eligible patients. Adults (>=18 years) that were
either CHD/CHD equivalent or nonCHD with multiple risk
factors and prescribed lipid lowering therapy were eligible. Date
of ﬁrst LLD was considered as index date, medical records were
reviewed by physicians to collect patient characteristics, baseline
and follow-up laboratory values, treatment, and resources use
data. RESULTS: A total of 440 patients (71% CHD/CHD equiv-
alent patients and 29% nonCHD with multiple risk factors) were
included in the study. Mean age was 61.5 years (SD 10.3), 51.5%
were female; mean baseline TC for CHD/CHD equivalent
patients was 6.9mmol/L (SD 1.6) and 7.3mmol/L (SD 1.4) for
nonCHD patients. Statins were initial LLD in 75.9% patients
followed by ﬁbrates (23.6%). The majority (87%) were initiated
either on simvastatin 10mg or simvastatin 20mg, or equipotent
statin. Of the patient not at goal at baseline 31% CHD and 23%
nonCHD patients attained TC goal at the end of the study
period. In a logistic model for goal attainment, patients with high
baseline TC (OR = 0.53 95% CI 0.35–0.80) and having ﬁbrates
as initial LLD (OR = 0.39 95% CI 0.22–0.73) compared to those
with statins as initial LLD were less likely to reach goal. CON-
CLUSIONS: Overall, only 15% attained TC goal on initial LLD,
and only an additional 11% attained goal after change in LLD,
resulting in 74% of patients not attaining goal with current LLD
dominated by statins. More effective therapy is needed in these




COSTS ASSOCIATED WITH ALTERNATIVE FETAL
CARDIOLOGY REFERRAL MODES: APPLICATION OF
PROPENSITY SCORE MATCHING
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OBJECTIVES: Propensity score matching (PSM) is a method
used to address selection bias in observational studies and to date
has been used mainly in survival analysis. This study has used
PSM when determining antenatal costs for alternative referral
modes (via telemedicine (TM) or direct referral) for obtaining
specialist advice for pregnant women at risk of a fetal cardiac
anomaly. METHODS: Three district hospitals (DH) in south-
east England were offered the use of a fetal cardiology telemedi-
cine service. Two hospitals (DH1 and DH3) continued to refer
all patients directly to London, while the third hospital (DH4)
used both referral modes. A logistic regression model was ﬁtted
to women in DH4 in order to predict what proportions of
women in DH1 and DH3 would have been seen via TM, had
that service been taken up. PSM was then used to match “TM”
cases to “direct referral” cases. A total cost per woman was
obtained for all antenatal resource use incurred during the study
and the costs were adjusted for those predicted as TM cases.
Finally, the costs for the predicted modes and matched modes
were compared. RESULTS: The logistic regression model pre-
dicted 153 women be assessed via TM and the remainder (n =
84) as direct referrals. Mean antenatal cost per patient for the
TM group was slightly higher (stg606), although not signiﬁ-
cantly so, compared with the direct referral group (stg561). After
applying PSM, 66 TM cases were matched to 55 direct cases.
The magnitudes of the PSM costs (TM group, stg671, and direct
group, stg551) were similar to the logistic regression model.
Comparisons of cost results by referral mode and analytical
method were not statistically signiﬁcant. CONCLUSIONS: PSM
indicated that the cost results from the logistic regression model
were reliable. We conclude that there is a role for PSM in eco-
nomic evaluation.
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OBJECTIVE: Administrative claims data are widely used to
study disease treatment patterns and costs. A valid, claims-based
deﬁnition method is needed to identify patients with chronic
angina (CA) from these data. METHODS: Five cardiologists and
one internist with claims-coding expertise developed an initial
series of increasingly speciﬁc, claims-based deﬁnitions of CA.
Claims data from 2001 to 2002 were used to determine the
number and demographic characteristics of patients who met
these criteria. This information was used to determine a ﬁnal 
deﬁnition for patients with CA that has acceptable levels of 
qualitatively assessed sensitivity and speciﬁcity. RESULTS: The
panel reviewed relative patient count and demographic infor-
mation and developed the following claims-based deﬁnition for
CA: Patients aged ° 35 years who were: a) diagnosed at least
twice with CA (ICD-9-CM codes 413.xx) and ﬁlled two nitrate,
beta-blocker or calcium channel blocker prescriptions with at
least 30 days between prescriptions; b) ﬁlled two nitrate pre-
scriptions, were diagnosed with chest pain (ICD-9-CM 786.50,
786.51 or 786.59), and were either diagnosed with coronary
artery disease (CAD) or had a CAD-related procedure; or c) ﬁlled
two nitrate prescriptions with at least 30 days between pre-
scriptions, were diagnosed with CAD and had one CA claim.
CONCLUSIONS: Patients with CA can be identiﬁed from
administrative claims data with different levels of speciﬁcity and
sensitivity. More studies are needed to conﬁrm criteria validity
of these criteria and to examine the clinical and economic impact
of CA in contemporary medical practice.
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